Chimeric Therapeutics Ltd - Asset Resilience Ratio

Latest as of December 2025: 42.22%

Chimeric Therapeutics Ltd (CHM) has an Asset Resilience Ratio of 42.22% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check CHM capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

AU$2.50 Million

≈ $1.77 Million USD Cash + Short-term Investments

Total Assets

AU$5.93 Million

≈ $4.20 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2022)

This chart shows how Chimeric Therapeutics Ltd's Asset Resilience Ratio has changed over time. See Chimeric Therapeutics Ltd balance sheet quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Chimeric Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CHM company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$2.50 Million	42.22%
Short-term Investments	AU$0.00	0%
Total Liquid Assets	AU$2.50 Million	42.22%

Asset Resilience Insights

Very High Liquidity: Chimeric Therapeutics Ltd maintains exceptional liquid asset reserves at 42.22% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Chimeric Therapeutics Ltd Industry Peers by Asset Resilience Ratio

Compare Chimeric Therapeutics Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
CSL Ltd AU:CSL	Biotechnology	0.41%
BB Biotech AG SW:BION	Biotechnology	0.05%
Concord Biotech Limited NSE:CONCORDBIO	Biotechnology	18.00%
Pharming Group NV AS:PHARM	Biotechnology	7.13%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Clarity Pharmaceuticals Ltd AU:CU6	Biotechnology	73.99%
Yantai Zhenghai Bio-Tech Co Ltd SHE:300653	Biotechnology	56.48%

Annual Asset Resilience Ratio for Chimeric Therapeutics Ltd (2021–2022)

The table below shows the annual Asset Resilience Ratio data for Chimeric Therapeutics Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-06-30	52.70%	AU$18.38 Million ≈ $13.01 Million	AU$34.88 Million ≈ $24.68 Million	-8.69pp
2021-06-30	61.39%	AU$22.41 Million ≈ $15.86 Million	AU$36.50 Million ≈ $25.83 Million	--

pp = percentage points

About Chimeric Therapeutics Ltd

AU:CHM Australia Biotechnology

Market Cap

$2.38 Million

AU$3.37 Million AUD

Market Cap Rank

#29763 Global

#1739 in Australia

Share Price

AU$0.07

Change (1 day)

-7.14%

52-Week Range

AU$0.00 - AU$0.21

All Time High

AU$0.39